Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Value Of Cytokeratin 5/6 Immunostaining In Distinguishing Epithelial Mesothelioma Of The Pleura From Lung Adenocarcinoma.
Published 1998 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
The immunohistochemical diagnosis of mesothelioma is commonly made by using a battery of antibodies that reacts with lung adenocarcinomas but not with epithelial mesotheliomas. Only recently have markers that are often expressed in mesotheliomas but not in adenocarcinomas been recognized. Some of these markers, however, require frozen tissue sections, whereas others are not commercially available, or their value remains controversial. In a recent publication, it was suggested that immunostaining for cytokeratin 5/6 could assist in distinguishing epithelial mesothelioma from lung adenocarcinoma. To determine the practical value of cytokeratin 5/6 immunostaining in the diagnosis of mesothelioma, 40 formalin-fixed, paraffin-embedded epithelial pleural mesotheliomas, 30 pulmonary adenocarcinomas, 93 nonpulmonary adenocarcinomas, 15 squamous carcinomas of the lung, 5 large cell undifferentiated carcinomas of the lung, and 12 metastatic transitional cell carcinomas to the lung were stained with the same antibody, which was obtained from a commercial source. Cytokeratin 5/6 reactivity was observed in all 40 mesotheliomas, but there was none in any of the 30 pulmonary adenocarcinomas. Focal or weak reactivity was observed in 14 of 93 nonpulmonary adenocarcinomas (10 of 30 ovarian, 2 of 10 endometrial, 1 of 18 breast, I of 7 thyroid, 0 of 10 kidney, 0 of 10 colonic, and 0 of 8 prostatic). All 15 squamous carcinomas of the lung, 6 of 12 transitional cell carcinomas metastatic to the lung, and 3 of 5 large cell undifferentiated carcinomas of the lung expressed cytokeratin 5/6. It is concluded that cytokeratin 5/6 immunostaining is not only useful in separating epithelial pleural mesotheliomas from pulmonary adenocarcinomas but also can assist in distinguishing epithelial mesotheliomas from nonpulmonary adenocarcinomas metastatic to the pleura.
This paper references
Intermediate filaments: a review of the basic biology.
R. Nagle (1988)
Cytokeratins in normal lung and lung carcinomas
G. Blobel (1984)
CD44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma
R. Attanoos (1997)
The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies.
N. Ordóñez (1997)
The diagnostic value of thrombomodulin immunolocalization in serous effusions.
V. Ascoli (1995)
Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblast of human placenta
I. Maruyama (1985)
The intermediate filament cytoskeleton of malignant mesotheliomas and its diagnostic significance.
G. Blobel (1985)
Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma.
C. L. Collins (1992)
Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium.
K. Chang (1992)
The Roles of Immunohistochemistry and Electron Microscopy in Distinguishing Epithelial Mesothelioma of the Pleura from Adenocarcinoma
N. Ordóñez (1996)
Value of thrombomodulin immunostaining in the diagnosis of mesothelioma
N. Ordóñez (1997)
Mesothelioma‐binding antibodies: thrombomodulin, OV 632 and HBME‐1 and their use in the diagnosis of malignant mesothelioma
R. Attanoos (1996)
Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.
S. Hsu (1981)
Monoclonal antibodies against mesothelial membrane antigen discriminate between malignant mesothelioma and lung adenocarcinoma
Rolf A. Stahel (1988)
The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells
R. Moll (1982)
Calretinin: a novel immunocytochemical marker for mesothelioma.
C. Doglioni (1996)
Monoclonal Antibody K1 Reacts With Epithelial Mesothelioma but not With Lung Adenocarcinoma
K. Chang (1992)
Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.
N. Ordóñez (1998)
Value of thrombomodulin immunostaining in the diagnosis of transitional cell carcinoma: a comparative study with carcinoembryonic antigen
N. Ordóñez (1997)
The roles of protein C and thrombomodulin in the regulation of blood coagulation.
C. Esmon (1989)
Immunohistochemical localization of thrombomodulin in chorionic diseases of the uterus and choriocarcinoma of the stomach. A comparative study with the distribution of human chorionic gonadotropin
S. Yonezawa (1988)
Antigen Unmasking in Formalin-Fixed Routinely Processed Paraffin Wax-Embedded Sections by Pressure Cooking: A Comparison with Microwave Oven Heating and Traditional Methods
K. Miller (1995)
Molecular and cellular biology of intermediate filaments.
P. Steinert (1988)
Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues.
A. Han (1997)
Expression of keratin 5 as a distinctive feature of epithelial and biphasic mesotheliomas
R. Moll (1989)
Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.
N. Ordóñez (1998)
Classification of human epithelia and their neoplasms using monoclonal antibodies to keratins: strategies, applications, and limitations.
D. Cooper (1985)
ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies.
C. O'hara (1990)
The Immunohistochemical Diagnosis of Mesothelioma: Differentiation of Mesothelioma and Lung Adenocarcinoma
N. Ordóñez (1989)
Anti‐cytokeratin 5/6: a positive marker for epithelioid mesothelioma
J. Clover (1997)
Immunohistochemical localization of thrombomodulin in normal human skin and skin tumours
D. Jackson (1995)
Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma.
K. Amin (1995)
The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas.
A. Peralta Soler (1995)
Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME‐1 expression
A. Bateman (1997)
Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma.
R. Brown (1993)
Newly marketed tissue markers for malignant mesothelioma: immunoreactivity of rabbit AMAD-2 antiserum compared with monoclonal antibody HBME-1 and a review of the literature on so-called antimesothelioma antibodies.
A. Donna (1997)
Thrombomodulin as a marker for vascular tumors. Comparative study with factor VIII and Ulex europaeus I lectin.
S. Yonezawa (1987)
Expression of a 130-kDa mesothelial and ciliated cell Ag (MCp130) in normal and developing human and rat lung and its role as a diagnostic marker for mesotheliomas and tumors of the female reproductive system.
G. Singh (1995)
The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval.
J. R. Riera (1997)
This paper is referenced by
Pathologic characterization and differential diagnosis of malignant peritoneal mesothelioma.
N. Ordóñez (2007)
Management of patients with metastatic cancer of unknown primary.
L. Ghosh (2005)
Epithelial mesothelioma with deciduoid features: report of four cases.
N. Ordóñez (2000)
Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer
P. Cossu-Rocca (2015)
Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies.
F. Roberts (2001)
Sex difference in diffuse malignant peritoneal mesothelioma
T. Yan (2006)
Prognostic Indicators for Patients Undergoing Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma†
T. Yan (2006)
Neoplasms of the Pleura
S. Hammar (2008)
Diagnostic use of muscle markers in the cytologic evaluation of serous fluids.
A. Afify (2002)
Value of the Mesothelium-Associated Antibodies Thrombomodulin, Cytokeratin 5/6, Calretinin, and CD44H in Distinguishing Epithelioid Pleural Mesothelioma from Adenocarcinoma Metastatic to the Pleura
P. Cury (2000)
Comparison of Clinicopathological Parameters and Molecular Classification of Breast Cancers
K. Indumathi (2015)
Podoplanin is a Highly Sensitive and Specific Marker to Distinguish Primary Skin Adnexal Carcinomas From Adenocarcinomas Metastatic to Skin
Haohai Liang (2007)
Significance of immunohistochemistry in accurate characterization of malignant tumors.
Z. Ahmed (2006)
IMMUNOHISTOCHEMICAL DETERMINATION OF PRIMARY SITES OF CARCINOMAS
A. Gown (1999)
The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study
N. Ordóñez (2006)
The role of immunohistochemistry in distinguishing squamous cell carcinoma from mesothelioma and adenocarcinoma in pleural effusion.
Q. Li (2006)
Malignant pleural mesothelioma.
L. Ho (2001)
Recommendations for the reporting of pleural mesothelioma.
K. Butnor (2007)
Malignant Pleural Mesothelioma Diagnosed by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration
Byungju Kang (2013)
The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas
T. Tot (2001)
Advances in clinical research and management of diffuse peritoneal mesothelioma.
M. Deraco (2007)
Primary peritoneal mesothelioma: case series and literature review.
H. Sharma (2011)
Anatomopathologie des tumeurs et pseudo-tumeurs primitives pleurales
D. Salameire (2006)
Chapter 7 – Immunohistology of Metastatic Carcinoma of Unknown Primary
D. Dabbs (2006)
Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers
J. Trupiano (2004)
34&bgr;E12 Cytokeratin Immunodetection in the Differential Diagnosis of Neuroendocrine Carcinomas of the Breast
M. Papotti (2001)
A clinicopathologic study of 100 cases of pulmonary sclerosing hemangioma with immunohistochemical studies: TTF-1 is expressed in both round and surface cells, suggesting an origin from primitive respiratory epithelium.
M. Devouassoux-Shisheboran (2000)
Risk factors and biomarkers for malignant mesothelioma
Vasiliki Panou (2019)
Lower Gastrointestinal Tract and Microsatellite Instability
J. Li (2011)
Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores.
N. Goldstein (2002)
Diagnostic utility of D2‐40 and podoplanin in effusion cell blocks
R. Bhalla (2007)
Diagnostic Use of Muscle Markers in the Cytologic Evaluation of Serous Fluids
A. Afify (2002)See more